Press Releases :: CohBar, Inc. (CWBR)

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

Dec 16, 2019 9:00am EST

CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis

Nov 06, 2019 4:04pm EST

CohBar Reports Third Quarter 2019 Financial Results and Business Update

Nov 05, 2019 9:00am EST

CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity

Oct 24, 2019 9:00am EDT

CohBar to Announce 2019 Third Quarter Financial Results and Provide Business Update on November 6, 2019

Oct 23, 2019 8:45am EDT

CohBar Expands Board with Biotech Veteran Misha Petkevich

Oct 15, 2019 9:00am EDT

CohBar to Present at the 2019 BIO Investor Forum

Sep 18, 2019 9:00am EDT

CohBar to Present at the 2019 Cantor Global Healthcare Conference

Aug 07, 2019 4:05pm EDT

CohBar Reports Second Quarter 2019 Financial Results and Business Update

Jul 31, 2019 4:05pm EDT

CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019

Jun 10, 2019 9:00am EDT

CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions